Pinjin Hu
Overview
Explore the profile of Pinjin Hu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
1614
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yao J, Peng X, Zhong Y, Su T, Bihi A, Zhao J, et al.
Front Med (Lausanne)
. 2023 Aug;
10:1105981.
PMID: 37554510
Objectives: Ustekinumab (UST) optimization strategies, including shortening intervals and intravenous reinduction, should be administered to patients with partial or loss of respond. Evidence comparing these types of optimization treatments is...
2.
Li P, Chao K, Hu Z, Qin L, Yang T, Mao J, et al.
Front Nutr
. 2023 Jul;
10:1138506.
PMID: 37441519
Introduction: Thiopurines, azathiopurine (AZA) and mercaptopurine (6-MP) have been regularly used in the treatment of inflammatory bowel disease (IBD). Despite optimized dosage adjustment based on the NUDT15 genotypes, some patients...
3.
Yao J, Zhou J, Zhong Y, Zhang M, Peng X, Zhao J, et al.
Med Phys
. 2023 Apr;
50(6):3862-3872.
PMID: 37029097
Background: Identifying patients with aggressive Crohn's disease (CD) threatened by a high risk of early onset surgery is challenging. Purpose: We aimed to establish and validate a radiomics nomogram to...
4.
Yao J, Zhang H, Su T, Peng X, Zhao J, Liu T, et al.
J Clin Med
. 2023 Feb;
12(3).
PMID: 36769587
There is insufficient evidence to confirm the efficacy of ustekinumab (UST) in promoting fistula closure in perianal fistulizing Crohn's disease (CD) patients. We aimed to evaluate the efficacy of UST...
5.
Yang H, Kurban M, Li M, Huang Z, Lin H, Hu P, et al.
Gastroenterol Rep (Oxf)
. 2022 Dec;
10:goac073.
PMID: 36523791
No abstract available.
6.
Yang H, Li B, Guo Q, Tang J, Peng B, Ding N, et al.
Aliment Pharmacol Ther
. 2022 Feb;
55(7):764-777.
PMID: 35141914
Background: Ustekinumab is effective in treating Crohn's disease (CD) and ulcerative colitis (UC). However, the loss of response (LOR) to ustekinumab and the efficacy of dose escalation have not been...
7.
Li J, Liu Z, Hu P, Wen Z, Cao Q, Zou X, et al.
BMC Gastroenterol
. 2022 Feb;
22(1):44.
PMID: 35120446
Background: Prevalence of inflammatory bowel disease (IBD) is increasing in China. The EXPLORE study evaluated the incidence and indicators of suboptimal responses to first-line anti-tumor necrosis factor (TNF) in patients...
8.
Yao J, Zhang M, Wang W, Peng X, Zhao J, Liu T, et al.
BMC Gastroenterol
. 2021 Oct;
21(1):380.
PMID: 34663208
Background: Ustekinumab (UST), a newly-used biologic targeting p40 subunit of IL12 and IL23 in China, exerts a confirmed therapeutic effect on the induction and maintenance therapies for refractory Crohn's disease...
9.
Chao K, Huang Y, Zhu X, Tang J, Wang X, Lin L, et al.
Aliment Pharmacol Ther
. 2021 Sep;
54(9):1124-1133.
PMID: 34563096
Introduction: Thiopurine S-methyltransferase (TPTM) is a well known biomarker for thiopurine-induced leucopenia, which has limited value in Asia. Instead, NUDT15 C415T is a promising predictor in Asia. Aims: To explore...
10.
Yang Q, Tang J, Ding N, Chao K, Li M, Huang Z, et al.
Nutr Clin Pract
. 2021 Jul;
37(2):366-376.
PMID: 34245474
Background: Conventional treatment for Crohn disease (CD) in pregnancy includes mesalamine, thiopurine, and anti-tumor necrosis factor (TNF)-α agents. However, women may abstain because of complications, nonresponse, or potential adverse outcomes....